UNSPSC 51391901: Dilazep

This classification denotes an alpha-adrenergic agonist with the molecular formula C31H44N2O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F8KLC2BD5Z, chemically known as tetrahydro-1h-1,4-diazepine-1,4(5h)-dipropanol 3,4,5-trimethoxybenzoate (diester) but generally known as dilazep, which bears US NIH Compound Identifier 3074. European Medicines Agency schedules Dilazep in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07144MIG.

UNSPSC 51391901 Dilazep is a Commodity code that in recent state and local procurement reflects a mismatch between its nominal pharmaceutical scope and actual buying patterns. The single recent opportunity tagged under this code—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and drug deactivation systems for community health initiatives, not dilazep specifically. Seminole County, a county-level health authority, is the issuing body represented in current activity. The procurement seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must include shipping and delivery costs in their proposals, comply with drug-free workplace certification and E-Verify requirements, maintain workers' compensation and commercial general liability insurance, and accept a three-month probationary termination period. The contract term runs two years with a one-year renewal option and may be funded through FEMA, triggering adherence to federal environmental regulations.

The code shows minimal recent activity and little evidence of systematic state and local procurement volume. Geographic visibility is limited to Florida based on the single solicitation. Seminole County released the IFB on July 10, 2023, with questions due July 21, 2023, and final responses due July 26, 2023, at 2:00 pm. The procurement does not designate set-asides for disadvantaged enterprises. The mismatch between the code's pharmaceutical nomenclature and the actual goods being solicited—over-the-counter harm-reduction and emergency medical supplies rather than dilazep—suggests this code may be a tagging error in the source system and does not represent active state and local procurement demand for the drug itself.